Search

Your search keyword '"Ahluwalia N"' showing total 352 results

Search Constraints

Start Over You searched for: Author "Ahluwalia N" Remove constraint Author: "Ahluwalia N"
352 results on '"Ahluwalia N"'

Search Results

1. WS06.03 Efficacy and safety of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in people with cystic fibrosis and ELX/TEZ/IVA-responsive, non-F508del genotypes: a phase 3, randomised, placebo-controlled trial

3. Objective randomised blinded investigation of therapeutic ablation versus cardioversion for persistent atrial fibrillation- outcomes of the feasibility

8. 137 Long-term safety and efficacy of elexacaftor-tezacaftor-ivacaftor in children aged 2 and older with cystic fibrosis and at least one F508del allele: 48-week results of an open-label extension study

9. 133 Long-term safety and efficacy of elexacaftor-tezacaftor-ivacaftor in children aged 6 and older with cystic fibrosis and at least one F508del allele: 144-week results of an open-label extension study

11. 169 A phase 4, fully decentralized clinical trial to evaluate physical activity and cough frequency in patients with cystic fibrosis using wearable technology

12. Transseptal puncture for left atrial ablation: risk factors for cardiac tamponade and a proposed causative classification system

13. 163 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children 6 years and older with cystic fibrosis and at least one F508del alleles: 96-week interim results from an open-label extension study

14. 170 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from an open-label extension study

15. 185 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating or residual function mutation

18. Erratum for Long‐term outcomes of index cryoballoon ablation or point‐by‐point radiofrequency ablation in patients with atrial fibrillation and systolic heart failure. J Cardiovasc Electrophysiol. 2021;32:941–948.

19. 562: Elexacaftor/tezacaftor/ivacaftor in children aged 6 and older with cystic fibrosis and at least 1 F508del allele: Interim results from a Phase 3 open-label extension study

22. A Phase 3 open-label study of ELX/TEZ/IVA in children 6 through 11 years of age with CF and at least one F508del allele

23. Long‐term outcomes of index cryoballoon ablation or point‐by‐point radiofrequency ablation in patients with atrial fibrillation and systolic heart failure

32. An Open-Label Extension (OLE) study of Tezacaftor/Ivacaftor (TEZ/IVA) in patients (PTS) ≥ 12 years with cystic fibrosis (CF) Homozygous for F508DEL-CFTR (F/F) or Heterozygous for F508DEL-CFTR and a residual function mutation (F/RF)

45. Apport des biomarqueurs de l’adiosité, de l’inflammation et de la fonction endothéliale dans la prédiction du diabète de type 2 au sein de la cohorte SU.VI.MAX

46. Adherence to Mediterranean diet reduces the risk of metabolic syndrome: a prospective study

47. OP0209 Soluble Ephrin-B2 Ectodomain Contributes to the Pathogenesis of Systemic Sclerosis

48. Trends in overweight prevalence among 11-, 13- and 15-year-olds in 25 countries in Europe, Canada and USA from 2002 to 2010

50. Overweight in school-aged children and its relationship with demographic and lifestyle factors: results from the WHO-Collaborative Health Behaviour in School-aged Children (HBSC) Study

Catalog

Books, media, physical & digital resources